A team of researchers from Children’s Hospital of Philadelphia (CHOP) used a new method of pinpointing potential disease-causing changes in the genome to identify two new potential therapeutic targets for lupus, while also paving the way for more accurately identifying disease-causing variations in other autoimmune disorders.Read more
By mapping molecular changes in the genome over time, UC San Diego researchers developed a formula to more accurately compare dog age to human age — a tool that could also help them evaluate how well anti-aging products work.Read more
It is with great pleasure that Ludwig Cancer Research announces the appointment of Yang Shi as Member of the Oxford Branch of the Ludwig Institute for Cancer Research.Read more
The University of Illinois at Chicago received $8.2 million from the National Institute on Alcohol Abuse and Alcoholism to continue the Center for Alcohol Research in Epigenetics and its research on how alcohol affects genes through epigenetics — chemical changes to DNA, RNA or proteins that alter the expression of genes without directly modifying them.Read more
Researchers at Mount Sinai have found that a novel class of genes known as long non-coding RNAs (lncRNAs) expressed in the brain may play a pivotal role in regulating mood and driving sex-specific susceptibility versus resilience to depression.Read more
UC San Diego School of Medicine researchers identified several genetic switches, or transcription factors, that determine whether or not liver cells produce collagen — providing a new therapeutic target for liver fibrosis.Read more
Researchers at Penn Medicine created a new mouse model that allows investigators to closely track the defects in sperm from the early stages of sperm development through fertilization and on. The model can lead to a better understanding of not only infertility in men—and ways to potentially reverse it.Read more
Epigenetic disorders are more common among children born through assisted reproductive technology. A new mouse study suggests that the fertility treatments themselves are to blame, not the age of the mother.Read more
NYU Langone Health and its Perlmutter Cancer Center have launched clinical whole genome DNA methylation profiling for patients with brain tumors.
This leading-edge molecular assay utilizes DNA epigenetic signatures and artificial intelligence with machine learning to correctly identify and subtype brain tumors. NYU Langone Health is the first Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory in the United States to receive state approval (New York State Department of Health) for whole genome DNA methylation for diagnosis and classification of brain tumors.